Current Medical Research and Opinion · 2002 · 161 citations · 23 references
MedicineNeurologyPharmacologyDementiaNeuropharmacologyNeuropsychiatryAntipsychotic PharmacotherapyAntipsychotic TherapyCholinergic PharmacologyCognitive ImpairmentDementia TreatmentParkinson DiseaseAntipsychotic Use In DementiaCholinergic Dysfunction In NeurodegenerationCognitive Enhancement By Cholinergic AgentsExtrapyramidal SignsParkinson Disease Dementia TreatmentPharmacological Treatment Of DementiaTreatment Of Cognitive SymptomsVisual Hallucinations
Parkinson's disease patients may suffer from cognitive impairment and behavioural problems such as apathy, personality changes, speech disturbances and visual hallucinations (Parkinson's disease dementia). However, there is currently no recommended treatment for Parkinson's disease dementia and antipsychotic agents can worsen extrapyramidal symptoms, making them unsuitable for patients with this condition. The observation that patients with Parkinson's disease dementia have extensive cholinergic deficits led to the hypothesis that cholinesterase inhibitors may provide benefits for patients with this condition. Here, we present a case series of patients with Parkinson's disease and dementia who we treated with rivastigmine, a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) that shows brain region-selectivity. The introduction of rivastigmine led to improvements in cognitive and functional abilities, as well as the resolution of behavioural problems and visual hallucinations. Rivastigmine was well tolerated by our patients when the dose was escalated slowly, including one patient who had previously experienced severe side-effects with the AChE-selective inhibitor donepezil. Despite the large number and range of concomitant medications being received by the patients, no side-effects thought to be related to drug-drug interactions were reported. A large, placebo-controlled study is warranted to ascertain the full clinical profile of rivastigmine in Parkinson's disease dementia.
23
Neuroleptic sensitivity in patients with senile dementia of Lewy body type.
Ian G. McKeith, Andrew Fairbairn, R. H. Perry et al. · BMJ · 1992 · 624 citations · Full text
Medicine, Neurology, Psychiatry +17
Jp Corey-Bloom · Medical Entomology and Zoology · 1998 · 469 citations